US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexeo Therapeutics

9.68

+0.46004.99%

Volume:158.83K

Turnover:1.48M

Market Cap:673.98M

PE:-3.03

High:9.68

Open:9.23

Low:9.23

Close:9.22

52wk High:11.72

52wk Low:1.45

Shares:69.63M

Float Shares:45.01M

Volume Ratio:1.02

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1956

EPS(LYR):-3.0934

ROE:-75.32%

ROA:-41.91%

PB:4.88

PE(LYR):-3.13

Loading ...

Overview Company News Filings

Lexeo Therapeutics Inc -Q2 Loss per Share $0.60

THOMSON REUTERS

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Initiated at Outperform by Oppenheimer

Lexeo Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $20

THOMSON REUTERS

Lexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics Inc. Conducted Virtual Annual Stockholders Meeting

BRIEF-Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders

MT Newswires Live

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs

Lexeo Therapeutics Is Maintained at Overweight by JP Morgan

Press Release: Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

CEO Richard Nolan Reports Disposal of Common Shares in Lexeo Therapeutics Inc

Lexeo Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Lexeo Therapeutics Inc. Files Amendment to 10-Q Annual Report

Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating

MT Newswires Live

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate

Press Release: Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LXEO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":9.68,"timestamp":1761055800627,"preClose":9.22,"halted":0,"volume":158833,"delay":0,"floatShares":45005000,"shares":69626214,"eps":-3.195553,"marketStatus":"Trading","change":0.46,"latestTime":"10-21 10:10:09 EDT","open":9.23,"high":9.68,"low":9.23,"amount":1484770.884,"amplitude":0.048807,"askPrice":9.69,"askSize":374,"bidPrice":9.66,"bidSize":262,"shortable":3,"etf":0,"ttmEps":-3.195553,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1761076800000},"marketStatusCode":2,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":9.22,"preHourTrading":{"tag":"盘前","latestPrice":9.23,"preClose":9.22,"latestTime":"09:29 EDT","volume":2908,"amount":26849.578540000002,"timestamp":1761053355078},"postHourTrading":{"tag":"盘后","latestPrice":9.5,"preClose":9.22,"latestTime":"19:40 EDT","volume":7659,"amount":70984.86,"timestamp":1761003657074},"volumeRatio":1.019292,"impliedVol":1.1322,"impliedVolPercentile":0.3935},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":45005000,"roa":"-41.91%","roe":"-75.32%","lyrEps":-3.093449,"volumeRatio":1.019292,"shares":69626214,"dividePrice":0,"high":9.68,"amplitude":0.048807,"preClose":9.22,"low":9.23,"week52Low":1.45,"pbRate":"4.88","week52High":11.72,"institutionHeld":0,"latestPrice":9.68,"committee":-0.176101,"eps":-3.195553,"divideRate":0,"volume":158833,"delay":0,"ttmEps":-3.195553,"open":9.23,"prevYearClose":6.58,"prevWeekClose":9.58,"prevMonthClose":6.64,"prevQuarterClose":6.64,"fiveDayClose":8.5,"twentyDayClose":5.35,"sixtyDayClose":4.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"LXEO","fiscalQuarterEnding":"2025/06","expectedEps":-0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2025-05-12","symbol":"LXEO","fiscalQuarterEnding":"2025/03","expectedEps":-0.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1754193600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2025-10-20","current":-2.88526,"percent":0.376596,"low":-8.903248,"twenty":-6.060519,"median":-3.639429,"eighty":-1.977104,"high":-0.6043,"avg":-3.820946,"sd":2.101567,"marketCap":517294967},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-04","current":-0.891258,"twenty":-6.338037,"median":-4.795483,"eighty":-2.464405,"marketCap":87640072},{"date":"2025-04-11","current":-0.732587,"twenty":-6.311324,"median":-4.74555,"eighty":-2.42393,"marketCap":72037483},{"date":"2025-04-17","current":-0.769723,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"marketCap":75689153},{"date":"2025-04-25","current":-1.238984,"twenty":-6.294572,"median":-4.621669,"eighty":-2.271508,"marketCap":121832978},{"date":"2025-05-02","current":-1.590085,"twenty":-6.292966,"median":-4.546304,"eighty":-2.190247,"marketCap":156357855},{"date":"2025-05-09","current":-1.012793,"twenty":-6.292343,"median":-4.461512,"eighty":-2.110502,"marketCap":99590991},{"date":"2025-05-16","current":-0.81978,"twenty":-6.289736,"median":-4.386933,"eighty":-1.999259,"marketCap":89607702},{"date":"2025-05-23","current":-0.935157,"twenty":-6.278497,"median":-4.373941,"eighty":-1.883139,"marketCap":102219157},{"date":"2025-05-30","current":-0.871396,"twenty":-6.262715,"median":-4.292656,"eighty":-1.737224,"marketCap":95249669},{"date":"2025-06-06","current":-0.992845,"twenty":-6.24372,"median":-4.263625,"eighty":-1.61652,"marketCap":108524884},{"date":"2025-06-13","current":-2.052375,"twenty":-6.232879,"median":-4.257819,"eighty":-1.598825,"marketCap":224338921},{"date":"2025-06-20","current":-2.127645,"twenty":-6.223303,"median":-4.238865,"eighty":-1.614228,"marketCap":232566510},{"date":"2025-06-27","current":-2.06491,"twenty":-6.203846,"median":-4.21373,"eighty":-1.629508,"marketCap":225709077},{"date":"2025-07-03","current":-2.198289,"twenty":-6.20262,"median":-4.195762,"eighty":-1.653954,"marketCap":240288372},{"date":"2025-07-11","current":-2.267449,"twenty":-6.200163,"median":-4.140386,"eighty":-1.70361,"marketCap":247848006},{"date":"2025-07-18","current":-2.104429,"twenty":-6.198104,"median":-4.103992,"eighty":-1.718889,"marketCap":230028868},{"date":"2025-07-25","current":-1.812971,"twenty":-6.182772,"median":-4.083635,"eighty":-1.764727,"marketCap":198170410},{"date":"2025-08-01","current":-2.336608,"twenty":-6.17781,"median":-4.06594,"eighty":-1.812971,"marketCap":255407640},{"date":"2025-08-08","current":-2.198289,"twenty":-6.166096,"median":-4.041907,"eighty":-1.86404,"marketCap":240288372},{"date":"2025-08-15","current":-2.26542,"twenty":-6.156275,"median":-3.900612,"eighty":-1.87168,"marketCap":258647483},{"date":"2025-08-22","current":-2.26069,"twenty":-6.144305,"median":-3.890098,"eighty":-1.890778,"marketCap":258107509},{"date":"2025-08-29","current":-2.251231,"twenty":-6.128418,"median":-3.827824,"eighty":-1.92165,"marketCap":257027562},{"date":"2025-09-05","current":-2.35055,"twenty":-6.121976,"median":-3.799992,"eighty":-1.925602,"marketCap":268367013},{"date":"2025-09-12","current":-2.449869,"twenty":-6.107404,"median":-3.74219,"eighty":-1.93461,"marketCap":279706464},{"date":"2025-09-19","current":-2.582295,"twenty":-6.103535,"median":-3.677964,"eighty":-1.952307,"marketCap":294825733},{"date":"2025-09-26","current":-3.07416,"twenty":-6.103378,"median":-3.543091,"eighty":-1.960886,"marketCap":350983015},{"date":"2025-10-03","current":-3.16875,"twenty":-6.084882,"median":-3.508838,"eighty":-1.966064,"marketCap":361782492},{"date":"2025-10-10","current":-3.878171,"twenty":-6.074043,"median":-3.510979,"eighty":-1.967068,"marketCap":442778573},{"date":"2025-10-17","current":-4.147751,"twenty":-6.062913,"median":-3.59126,"eighty":-1.975097,"marketCap":473557083},{"date":"2025-10-20","current":-4.530839,"twenty":-6.060519,"median":-3.639429,"eighty":-1.977104,"marketCap":517294967}],"updateTime":1761052932572},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559951753","title":"Lexeo Therapeutics Inc -Q2 Loss per Share $0.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2559951753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559951753?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:30","pubTimestamp":1755171003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nTUABLZPZD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2559195102","title":"Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559195102","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559195102?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:30","pubTimestamp":1755171000,"startTime":"0","endTime":"0","summary":"Breakthrough Therapy designation granted for LX2006 based oninterim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133352/0/en/Lexeo-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4539","LU0149725797.USD","LU0971096721.USD","BK4139","BK4535","CMC","IE00B1BXHZ80.USD","LU1363072403.SGD","BK4130","LU2746668461.USD","FA","LU0170899867.USD","IE00BFXG1179.USD","LU0882574139.USD","BK4006","LXEO","IE00BHPRN162.USD","IE00BKVL7J92.USD","LU2746668974.SGD","LU0267386448.USD"],"gpt_icon":0},{"id":"2555100833","title":"Lexeo Therapeutics Initiated at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2555100833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555100833?lang=en_us&edition=fundamental","pubTime":"2025-07-31 20:17","pubTimestamp":1753964220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 31, 2025 08:17 ET (12:17 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","LXEO"],"gpt_icon":0},{"id":"2555880020","title":"Lexeo Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Price Target $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2555880020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555880020?lang=en_us&edition=fundamental","pubTime":"2025-07-31 20:06","pubTimestamp":1753963563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nFWN3TS38T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2555264200","title":"Lexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2555264200","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555264200?lang=en_us&edition=fundamental","pubTime":"2025-07-31 00:46","pubTimestamp":1753893960,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics shares were 17% higher, at $4.78, after the company said that the Food and Drug Administration has granted breakthrough therapy designation to gene therapy LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich's ataxia.The clinical stage genetic medicine company said LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, intended to enable earlier patient access to therapies with expedited clinical development timelines.To date, 17 participants have been treated across two trials, and Lexeo is currently enrolling a prospective natural history study, which will serve as a concurrent external control arm for the registrational study.The company expects to initiate the registrational study by early 2026 and is actively working with FDA to finalize the statistical analysis plan.Breakthrough Therapy designation is intended to accelerate the developm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Lexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2549539245","title":"Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539245","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549539245?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886000,"startTime":"0","endTime":"0","summary":"Breakthrough Therapy designation based oninterim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/07/3110900/0/en/Lexeo-Therapeutics-Announces-FDA-Breakthrough-Therapy-Designation-for-LX2006-in-Friedreich-Ataxia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU0882574139.USD","IE00BHPRN162.USD","BK4139","BK4528","SAP","BK4585","LXEO","CMC","IE00BKVL7J92.USD","BK4023","FA","BK4006","LU0267386448.USD","BK4613","LU0170899867.USD","IE00B1BXHZ80.USD","BK4539","LU0971096721.USD","LU0149725797.USD","IE00BZ1G4Q59.USD","BK4588","LU1363072403.SGD","BK4130"],"gpt_icon":0},{"id":"2548048649","title":"Lexeo Therapeutics Inc. Conducted Virtual Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2548048649","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548048649?lang=en_us&edition=fundamental","pubTime":"2025-07-01 04:47","pubTimestamp":1751316468,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. held its virtual 2025 Annual Meeting of Stockholders on June 26, 2025. Stockholders elected Steven Altschuler, M.D. and Reinaldo Diaz as Class II Directors. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL5Zf9m6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2545828145","title":"BRIEF-Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2545828145","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545828145?lang=en_us&edition=fundamental","pubTime":"2025-06-24 19:34","pubTimestamp":1750764868,"startTime":"0","endTime":"0","summary":"BRIEF-Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA TherapeuticsJune 24 (Reuters) - Lexeo Therapeutics Inc LXEO.O:LEXEO T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nFWN3SR0JT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2543086630","title":"Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2543086630","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543086630?lang=en_us&edition=fundamental","pubTime":"2025-06-14 04:51","pubTimestamp":1749847918,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (LXEO) filed a registration statement Friday for the sale of about 41.6 million common shares on behalf of certain selling stockholders.The company won't receive any proceeds from the sale of shares by the investors.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2541070295","title":"US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2541070295","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541070295?lang=en_us&edition=fundamental","pubTime":"2025-06-06 02:11","pubTimestamp":1749147079,"startTime":"0","endTime":"0","summary":"US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs By Sneha  S K and Sriparna  RoyJune 5 (Reuters) - Health and Human Services Secretary Robert F. Kennedy Jr. said on ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL3N3S8183:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DYN","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","SRPT","IE00B2B36J28.USD","IE0009355771.USD","LXEO","BK4139","BK4588","BK4505","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2539275043","title":"Lexeo Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2539275043","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539275043?lang=en_us&edition=fundamental","pubTime":"2025-05-30 23:08","pubTimestamp":1748617680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 11:08 ET (15:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2538463262","title":"Press Release: Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2538463262","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538463262?lang=en_us&edition=fundamental","pubTime":"2025-05-27 19:31","pubTimestamp":1748345460,"startTime":"0","endTime":"0","summary":"Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy. Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors. \"This financing will enable Lexeo to build on its leadership in cardiac genetic medicines as we continue to advance our clinical stage pipeline, \" said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. \"With the support of an exceptional group of new and existing long-term investors, we believe we remain well-positioned to accelerate development of our programs and drive innovation with next-generation therapies that could redefine the treatment paradigm for devastating cardiovascular conditions.\". Lexeo intends to use net proceeds from the private placement to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes. The proceeds from this private","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","EQR","BK4585","LXEO","BK4082","FA","MDCO","BK4130","BK4215","BK4539","BK4535","BK4588","BK4139"],"gpt_icon":0},{"id":"2537625491","title":"CEO Richard Nolan Reports Disposal of Common Shares in Lexeo Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2537625491","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537625491?lang=en_us&edition=fundamental","pubTime":"2025-05-21 05:00","pubTimestamp":1747774854,"startTime":"0","endTime":"0","summary":"Richard Nolan Townsend, Chief Executive Officer and Director of Lexeo Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDLbJbDbd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2535396009","title":"Lexeo Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2535396009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535396009?lang=en_us&edition=fundamental","pubTime":"2025-05-16 19:37","pubTimestamp":1747395420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 07:37 ET (11:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2535814761","title":"Lexeo Therapeutics Inc. Files Amendment to 10-Q Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2535814761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535814761?lang=en_us&edition=fundamental","pubTime":"2025-05-15 18:03","pubTimestamp":1747303403,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. filed an amendment to the 10-Q annual report for the fiscal year ending March 31, 2025. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL4bkZpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2535775906","title":"Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2535775906","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535775906?lang=en_us&edition=fundamental","pubTime":"2025-05-13 20:57","pubTimestamp":1747141069,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (LXEO) has an average rating of buy and mean price target of $21.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO"],"gpt_icon":0},{"id":"2535724265","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2535724265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535724265?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:38","pubTimestamp":1747136280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2025 07:38 ET (11:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2534427211","title":"Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2534427211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534427211?lang=en_us&edition=fundamental","pubTime":"2025-05-12 22:08","pubTimestamp":1747058920,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryLexeo Therapeutics Inc LXEO.OQ reported a quarterly adjusted loss of 99 cents per share for the quarter ended Ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nL8N3RK1R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2534225072","title":"Lexeo Therapeutics Q1 EPS $(0.99) Misses $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534225072","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534225072?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:13","pubTimestamp":1747048405,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 28.57 percent decrease over losses of $(0.77) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45344017/lexeo-therapeutics-q1-eps-0-99-misses-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2534223741","title":"Press Release: Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2534223741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534223741?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:00","pubTimestamp":1747047600,"startTime":"0","endTime":"0","summary":"Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia  cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study. LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control. Phase 1/2 clinical trial of LX2020  currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025. Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to provide operational runway into 2027. \"Based on the highly encouraging clinical data shared to date, we believe LX2006 could be transformational and establish a new standard of care in FA cardiomyopathy,\" said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. \"We look forward to beginning enrollment in the CLAR","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4130","BK4539","FA","BK4535","BK4139","LXEO"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":61,"code":"91000000","status":"200"}]}}